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ABSTRACT
Background & objectives: Leishmaniasis has an annual incidence of 0.5–1.5 million new cases and is endemic in
88 countries throughout the world. About 90% of cases of cutaneous leishmaniasis (CL) are reported from seven
countries including Iran. Evidence suggests the increased annual incidence of this disease in Iran. Intracellular
protozoan parasite, Leishmania, is an obligatory parasite. Sandflies transfer infectious forms of the parasite or its
metacyclic promastigotes to its vertebrate hosts such as humans by biting. In order to review the epidemiology of
CL in Isfahan, Iran, factors such as incidence, disease causes, geographic features, age, and sex distribution,
nationality, and occupation of patients, and the clinical spectrum of disease were evaluated.
Methods: During the study, 1315 patients with CL, who referred to the Dermatology and Leishmaniasis Research
Center at Isfahan, were evaluated.
Results: The highest prevalence of CL was observed in fall (54%) and in northern areas of Isfahan (60.9%).
Although CL was prevalent in both men and women, it had higher incidence in men (61.8%). The majority of
patients (31.2%) aged 21–30 yr old. Most lesions were nodule-shaped (36.5%) and in upper extremities (48.3%)
particularly in men (32.4%). While 81.2% of the subjects were Iranian, others were Afghani or with other
nationalities. Most patients had multiple lesions on their bodies and 141 individuals (10.7%) had a previous
history of disease. Among all occupations, the highest prevalence of CL was detected in students (18.1%). The
response to treatment with compounds of meglumine antimoniate (glucantime) was better than other treatments.
Interpretation & conclusion: Unfortunately, the results showed that the prevalence of CL has been increasing
annually in some provinces of Iran, especially in Isfahan Province. Nevertheless, further studies are required to
determine the vectors, reservoirs, and species of disease and to design appropriate strategies to control the disease.
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INTRODUCTION
Leishmaniasis, a major global health and economic
issue, comprises a group of diseases caused by the proto-
zoan parasites of the genus Leishmania. Transmission of
leishmaniasis to mammals, including humans, requires
the bite of female phlebotomine sandflies1–3. Rodents
serve as animal reservoir hosts of this disease and infected
Rhombomys opimus, Meriones libycus and M. nesokia
have been found in Isfahan Province (Iran)4.
Clinical and epidemiological features of leish-
maniasis vary depending upon the interactive impact
of different factors such as parasites, hosts, vectors and
the involved environment. Among three clinical forms
(cutaneous, visceral, and mucocutaneous) of the disease,
cutaneous leishmaniasis has the highest prevalence in the
Middle East2, 5. Despite remarkable advancements in dis-
ease control, leishmaniasis is still a major health concern.
The World Health Organization (WHO) has, in fact, in-
troduced leishmaniasis as the sixth most important dis-
ease in tropical and subtropical areas6.
Two parasite species, i.e. Leishmania major and L.
tropica, are responsible for most of the cases of CL. Ur-
ban (dry) CL is caused by L. tropica and has been re-
ported in cities of Tehran, Shiraz, Mashhad, Nishabur,
Kerman, Bam, Rafsanjan and Khomeyni Shahr (Iran)7, 8.
Rural (wet) CL, caused by L. major, has been found in
vast areas of Iran including Isfahan, Sarakhs, Lotfabad,
Khuzestan, Kashmar, Kashan, Damghan and Dehloran9.
Although about 20,000 cases of the disease are annu-
ally reported from different areas of Iran, the actual rate has
been estimated to be five times higher10,11. The prevalence
of leishmaniasis in different provinces of Iran ranges from
1.8 to 37.9%6. As the disease keeps appearing at new sites
around the country, wide national and international invest-
ments and efforts have failed to eradicate it in Iran. Since
unsuccessful health and social activities to control leishma-
niasis have resulted in irreparable economic, social, and
psychological damages, the cutaneous leishmaniasis con-
trol program in Iran has sought to identify the epidemiologi-
cal characteristics of the disease at various sites12–16.
Isfahan Province, located in the center of Iran on green
plains of Zayandeh Rud River, has a high prevalence of
CL. The present study aimed to review the epidemiology 31 Karami et al: Assessing epidemiology of cutaneous leishmaniasis in Isfahan, Iran
of this disease in the city of Isfahan (the capital of Isfahan
Province).
MATERIAL & METHODS
This descriptive, analytical, cross-sectional study as-
sessed all individuals (n = 1733) who referred to the Der-
matology and Cutaneous Leishmaniasis Research Center
(Isfahan, Iran) due to suspected CL during 2007–08. Over-
all, 1315 patients (75.9%) had positive leishmanin skin
tests. After being examined by a physician in the health
center, the patients provided informed consents and com-
pleted a special questionnaire including age, sex, occu-
pation, lesion type, month and season of incidence, pre-
sumptive diagnosis, and type and duration of drug
consumption. The lesion sites were then biopsied to con-
firm the diagnosis of leishmaniasis. Following fixation
in methanol for 20–30 sec, the samples were stained with
Giemsa (20–30 min). If Leishmania amastigotes were
observed under the microscope, cutaneous leishmaniasis
was confirmed and the patient’s completed questionnaire
was evaluated.
Finally, the collected data were analyzed using
descriptive statistics and chi-square test in SPSS for
Windows version 16.0 (SPSS Inc., Chicago, IL, USA).
P-values < 0.05 were considered significant.
RESULTS
As indicated in Table 1, the prevalence of CL was
assessed in northern, southern, eastern, western, and cen-
tral Isfahan. While the northern area of the city had the
highest number of infected individuals (n=800; 60.9%), the
lowest rate was observed in southern areas (n=21; 1.6%).
Out of 1315 people with leishmaniasis skin lesions, 812
(61.8%) were males, and 503 (38.2%) were females. Chi-
square test showed a significant difference between the
prevalence of the disease in men and women (p <0.01).
The highest frequency (32.1%) of patients with cutane-
ous leishmaniasis was detected in 21–30 yr-old subjects.
However, the disease was found to infect all the age groups
(Table 2). The disease had the highest and lowest fre-
quency among 21–30 and >59 yr-old individuals, respec-
tively. Furthermore, >50% of samples with positive
leishmanin test belonged to the individuals younger than
30 are of the most active group of the population due to
their occupation, education, and activity.
Table 3 summarizes sites of lesions in different
months and seasons of the year. As seen, most lesions
Table 2. Frequency of cutaneous leishmaniasis in different age
groups of patients in Isfahan, Iran, during 2007–08
Age (yr) n (%)
< 10 266 (20.2)
11–20 235 (17.9)
21–30 422 (32.1)
31–40 149 (11.3)
41–50 154 (11.7)
>50 89 (6.8)
Total 1315 (100)
Table 1. Frequency distribution of people with cutaneous leishmaniasis (CL) based on their place of
residence in Isfahan, Iran, during 2007–08
Location Place of living Population People with CL Total
n (%) percentage
North 992 800 (60.9) 57.2
South 28 21 (1.6) 1.6
East 383 260 (19.8) 22.1
West 210 170 (12.9) 12.1
Center 120 64 (4.8) 6.9
Zeynabieh, Borkhar, Meymeh, Shahin Shahr, Malek Shahr,
Dolat Abad, Habib Abad, Khorzough, Dastjerd, Agha Ali
Abbas, Narmi Emamzadeh, Gorgab, Natanz and Badrud
Sepahan Shahr, Baharestan, Mobarakeh, Shahreza, Zarrin
Shahr, Dehaghan, Semirom and Margh-o-Mayar
Haftshouyeh, Jarghouyeh, Ziar, Khorasgan, North Bara’an,
Ghahjaverestan, Mohammad Abad, Eshkavand, Gavart,
Jolgeh, Ejieh, Varzaneh, Nuclear Plant and Shahid Beheshti
Airport
Lenjan, Khomeini Shahr, Najaf Abad, Koushk, Falavarjan,
Pirbakran, Zob Ahan Highway, Goldasht, Dorche, Jouzdan,
Asghar Abad and Kahrizsang
Areas around Kaveh Terminal, Sofeh Terminal, Zayanderoud
Terminal, Jey Terminal, Imam Square, Imam Ali Square,
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occur in upper extremities (34.3%) and during fall
(52.5%). Moreover, the majority of patients was Iranian
(81.2%) and infected in fall (51.7%).
As Table 4 shows, the majority of patients (54%) had
more than one lesion on their bodies. Moreover, the high-
est prevalence of multiple lesions was observed in fall
(52.6%). Table 5 shows the prevalence of the usual (clas-
sic) and ususual clinical forms of cutaneous leishmania-
sis among the patents in the city of Isfahan. As Table 6
shows, among various occupation, cutaneous leishmania-
sis had the highest prevalence in students (18%). Finally,
the most common treatment was intramuscular
meglumine antimoniate (Glucantime) (24.5%) (Table 7).
DISCUSSION
Cutaneous leishmaniasis is seen in most provinces of
Iran. It is an important health problem around the world
particularly in Mediterranean and African countries and
the Middle East. The spread of cutaneous leishmaniasis
from endemic to non-endemic regions of Iran (due to
environmental factors such as irregular immigration, de-
mographic changes, development of agriculture, and wa-
ter providing projects) and the consequent increase in the
prevalence of the disease have imposed a considerable
Table 3. Frequency distribution of patients with cutaneous leishmaniasis stratified based on months and seasons of
occurrence and lesion site (Isfahan, Iran, 2007–08)
Season Month Lesion sites
Head and face* Upper extremities** Lower extremities† More than one organ Total
n (%) n (%) n (%) n (%) number
Spring April 5 (14.7) 14 (41.2) 9 (26.5) 6 (17.6) 34 (100)
May 17 (29.3) 18 (31.1) 15 (25.9) 8 (13.8) 58 (100)
June 8 (17.1) 18 (38.3) 15 (31.9) 6 (12.8) 47 (100)
Total 30 (21.6) 50 (36) 39 (28.1) 20 (14.4) 139 (100)
Summer July 8 (24.2) 10 (30.3) 10 (30.3) 5 (15.2) 33 (100)
August 17 (18.7) 31 (34.1) 25 (27.5) 18 (19.8) 91 (100)
September 33 (20) 59  (35.8) 28  (17) 45 (27.3) 165 (100)
Total 58 (20.3) 100 (35) 63  (22.1) 68 (23.8) 289 (100)
Fall October 25 (10.7) 90 (38.6) 31  (13.3) 95 (40.8) 241 (100)
November 35 (13.5) 89 (34.4) 57  (22) 78 (30.1) 259 (100)
December 26 (13.8) 59 (31.4) 48 (25.5) 57 (30.3) 190 (100)
Total 86 (12.5) 238 (34.5) 136 (20) 230 (33.8) 690 (100)
Winter January 17 (15.5) 32 (29) 33 (30) 28 (25.5) 110 (100)
February 6 (14.3) 19 (45.2) 9 (21.4) 8 (91.1) 42 (100)
March 9 (20) 19 (42.2) 10 (22.2) 7 (15.6) 45 (100)
Total 32 (2.8) 70 (45.5) 52 (33.8) 43 (100) 197 (100)
Grand total (12 months) 206 (15.8) 458  (34.4) 290 (22.2) 361 (27.7) 1315 (100)
*Ear, forehead, eyes, cheeks, chin, and lips; **Neck, hand, chest, abdomen, and waist; †Legs, buttocks, and genitals.
Table 4. Frequency distribution of patients with one or multiple
leishmaniasis lesions stratified based on
different months and seasons (Isfahan, Iran, 2007–08)
Season Month Patients with Patients Total
one lesion with multiple n (%)
n (%) lesions n (%)
Spring April 22 (2.5) 12 (1.7) 34 (2.6)
May 36 (4.2) 19 (2.7) 58 (4.4)
June 29 (3.3) 18 (2.5) 47 (3.6)
Total 87 (10) 49 (6.9) 139 (10.6)
Summer July 23 (3.8) 10 (1.4) 33 (2.6)
August 50 (8.5) 41 (5.8) 91 (6.8)
September 72 (12) 93 (13.1) 165 (12.7)
Total 145 (24.3) 144 (20.3) 289 (22.1)
Fall October 80 (12) 164 (22.8) 244 (17.9)
November 99 (16.6) 160 (22.6) 259 (19.8)
December 83 (13.9) 106 (15) 189 (14.5)
Total 262 (42.5) 430 (60.4) 692 (52.6)
Winter January 60 (10) 50 (7.1) 110 (8.4)
February 24 (4) 18 (2.5) 42 (3.2)
March 25 (4.2) 20 (2.8) 45 (3.5)
Total 109 (18.2) 88 (12.4) 197 (15.1)
Grand total(12 months) 605 (46) 710 (54) 1315 (100) 33 Karami et al: Assessing epidemiology of cutaneous leishmaniasis in Isfahan, Iran
Table 5. Frequency distribution of usual and unusual clinical forms
of cutaneous leishmaniasis in Isfahan, Iran during 2007–08
Forms* Clinical forms Number Percentage
of infected of
people infection**
Usual form Papule 20 1.5
(Classic) Nodule 400 30.4
Ulcer Keratosis 385 29.3
More than one clinical 34 2.9
All classical 839 63.8
Unusual Impetigo 154 11.7
(Non- Hyperkeratosis 36 2.7
classic) Erysipeloid 25 1.9
Ecthyma 18 1.3
Warty 7 0.5
Sporotrichoid 4 0.3
Tumoral 2 0.2
Zostri 8 0.6
Volcano-shaped 200 15.2
Lupoid 16 1.2
Plaque 6 0.4
All non-classical 476 36.2
Total number of patients 1315 100
*According to Gramiccai & Gradoni19; **Percentage of infection has
been calculated considering the total number of patients with cutaneous
leishmaniasis.
Table 6. Prevalence of cutaneous leishmaniasis among patients
with different occupations in Isfahan, Iran during 2007–08
Job title Number Percentage
Physicians 2 0.2
Engineers 3 0.3
Nurses 6 0.5
Employees 66 5
Military* 75 5.7
Students** 237 18
Drivers 55 4.2
Workers 217 16.4
Childern 214 16.3
Housekeepers 218 16.5
Retired 23 1.8
Farmers 33 2.5
Stockmen 4 0.4
Self-employed+ 154 11.6
Unemployed 8 0.6
Total 1315 100
*Soldiers, police officers, security guards, and patrol polices; **School
or university students; +Tailor, panel maker, cabinet maker, quilter,
sales person, fireman, chef, surveyor, shoemaker, painter, draper, and
butcher.
economic and health burden on the society17, 18.
Almost all the cases of cutaneous leishmaniasis (90%)
occur in only seven countries, i.e. Iran, Afghanistan, Al-
geria, Brazil, Peru, Syria, and Saudi Arabia19. Iran not
only has a high prevalence of the disease, but it is also a
neighbor of Afghanistan and has close relationships and
great deals of trading with Syria and Saudi Arabia. Ap-
parently, such challenges increase the importance of the
disease.
Numerous studies in different parts of the world have
evaluated various aspects of cutaneous leishmaniasis.
They have assessed epidemiological aspects of the dis-
ease by considering descriptive indices such as age, sex,
occupation, and nationality20. The present cross-sectional
study tried to analyze the available statistics and demo-
graphic information to identify the relation of cutaneous
leishmaniasis with epidemiological factors using 1315
patients during one year. We found most patients to be
male. In a study in Shiraz and Qom (two cities in Iran) in
2008, 59.3% of the patients were male21. Similarly, a study
from Pakistan reported 56.6% of the patients with cuta-
neous leishmaniasis to be male22. The very higher inci-
dence of this disease in men compared to women can be
justified by men comprising the majority of seasonal im-
migrants as work labor, working in open environments
(farms and firms), wearing fewer parts of clothing than
women, travelling more in deserts and wastelands, and
having probably more contact with sandflies during
evening and night. Enhancing the knowledge of seasonal
workers who have to commute to endemic regions can
reduce the contact rate with sandflies15.
Most patients in the present study resided in the north-
ern part of Isfahan. Borkhar (a city in the north of Isfahan)
was the main disease site as it has suitable conditions for
living and reproduction of disease reservoir. On the other
hand, establishment of new residential and military zones
and entrance of non-indigenous people have increased
the prevalence of the disease and turned the city into a
hyperendemic region. Natanz is another highly infected
area in the north of Isfahan due to its active mice colo-
nies. On the other hand, Agha-Ali-Abbas pantheon, which
is located near Natanz, attracts many non-indigenous and
sensitive pilgrims. These people can be easily infected
during their visit since abundant haloxylon trees provide
a great habitat for mice colonies. Previous studies have
identified R. opimus and M. libycus in rodents of Natanz.
Furthermore, mice infected with R. opimus and M. nesokia
have been hunted in northern areas of Isfahan13.
Four species of sandflies (Phlebotomus ansari, P.
sergenti, P. caucasicus, and P. papatasi) have been rec-
ognized in human habitats of the five regions of Isfahan J Vector Borne Dis 50, March 2013 34
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Province. Therefore, both urban and rural types of CL
can occur in five regions of Isfahan. In addition, the ac-
tivity of rodents (with R. opimus) in Isfahan reaches its
peak during August–December13, 17.
According to our findings, frequency of cutaneous
leishmaniasis was significantly related with age. In gen-
eral, adults who live near disease sites and work in en-
demic areas are at higher risk of infection8.
While a study reported 51.1% of patients to the age
6–15 yr-old23, another research found the highest preva-
lence among 16–50 yr old individuals24. It can hence be
concluded that rates of infection in different age groups
depend upon the study location. In regions such as Isfahan
with abundant reservoirs and vectors, people’s high con-
tact rate with them, and great number of natives, 5–6 yr
old children are the most infected group13, 17. Since 90%
of the cases develop life-time immunity against the dis-
ease, it is very rare in adults and old people. However, in
other parts of the country where the number of local people
is low or the population is frequently altered, the disease
can be seen in all age groups25. The lesion site depends
on many factors including the type of sandfly, social and
cultural behavior of people, and climate. Most lesions in
the present study were in the upper extremities and face.
It is clear that the body areas which are not covered are
more exposed to bites of sandflies. Other studies in vari-
ous parts of Iran have also suggested most lesions to oc-
cur in upper extremities, face, head, neck, and hands26, 27.
Similar to previous research17, 28, multiple lesions were
more frequent than single lesions in our study. Multiple
lesions can result from receiving infected bites at differ-
ent times or insemination following scratching. They can
also be found along lymphatic vessels or in people with
underlying diseases such as acquired immune deficiency
syndrome (AIDS), renal problems, and diabetes which
attenuated the immune system17. Rafati et al21, Abbasi et
al29, and Hamzavi et al30 found >60% of the patients to
have more than one lesion on their bodies. Effects of CL
on beauty and general and mental health of the patients
necessitate more efficient measures to control and pre-
vent the disease.
According to Table 8, the highest incidence of CL
was observed in fall followed by summer. This finding
can be justified considering the biology of vector sandflies,
the main vectors in the studied area. Basically, CL in hu-
mans follows a seasonal pattern in regions where adult
Table 8. Prevalence of patients with cutaneous leishmaniasis stratified based on season and month of
infection, nationality, and history of the disease (Isfahan, Iran, 2007–08)
Season Month Previous infection Nationality
Yes No. Iranian Afghani Other* All
Once More than once n (%) n (%) n (%) n (%) nationalities
n (%) n (%) n (%)
Spring April 2 (1.8) – 32 (2.7) 29  (2.7) 5 (2.2) 1 (3.6) 35  (2.7)
May 5 (4.7) 1  (5.6) 53 (4.5) 14 (1.3) 5  (2.2) 0 19 (1.4)
June 2 (8.1) 1  (6.5) 45 (3.7) 53  (4.9) 6 (2.9) 1 (3.6) 60 (4.6)
Total 9  (8.5) 2  (2.1) 130 (10.9) 96  (9) 16  (7.3) 2 (7.2) 114 (8.7)
Summer July 2 (1.8) 1  (6.5) 31  (2.6) 32  (3) 1 (0.5) 1 (3.6) 34  (2.6)
August 15  (14) 3 (16.7) 78  (6.6) 82  (7.7) 11  (5) 2 (7.2) 95  (7.2)
September 25 (23.3) 2  (11.1) 143  (12) 137 (12.8) 31 (14) 3 (10.7) 171  (13)
Total 42 (38.8) 6 (33.4) 252 (21.2) 251 (23.6) 43 (19.5) 6 (21.4) 300 (22.8)
Fall October 7 (6.5) 2 (11.1) 212 (17.8) 193 (18) 44 (20.1) 7 (25) 244 (18.6)
November 18 (16.7) 4 (22.2) 241 (20.3) 214 (20.1) 45 (20.4) 2 (7.2) 261 (19.8)
December 8  (7.4) 2  (11.1) 181 (15.3) 145 (13.6) 43 (19.5) 5 (17.9) 193 (14.7)
Total 33 (30.7) 8 (44.4) 634 (53.4) 552 (51.7) 132  (60) 14 (50) 698 (53.1)
Winter January 15 (13.8) – 95  (7.9) 94  (8.8) 16  (7.3) 1 (3.6) 111 (8.4)
February 3  (2.7) 1  (5.6) 39  (3.3) 34  (3.2) 8  (3.7) 2 (7.2) 44  (3.3)
March 6  (5.6) 1 (5.6) 39  (3.3) 40  (3.7) 5  (2.2) 3 (10.7) 48  (3.7)
Total 24 (22.2) 2 (2.1) 173 (14.5) 168 (15.7) 29 (13.2) 6 (21.4) 203 (15.4)
Grand total(12 months) 108 (8.2) 18 (1.4) 1189 (90.4) 1067 (81.2) 220 (16.7) 28  (2.1) 1315 (100)
*Immigrants from Iraq, Pakistan, India, Malaysia, Bangladesh, Turkey, and tourists from other countries. J Vector Borne Dis 50, March 2013 36
sandflies’ growth is seasonal. In areas where adult
sandflies develop in spring and early summer, new cases
of CL usually appear at the end of summer or in fall31. In
contrast to our findings, a study in Pakistan32 reported
most cases of the disease in winter. Infections were found
to depend on type of CL, prevalence of the vector, and
disease reservoirs.
The majority of patients in this study were Iranian
(82.2%). Although the incidence of first-time disease was
the highest in fall, patients with a history of the disease
had new lesions mostly in summer. Moreover, in our par-
ticipants, classic forms of CL were more prevalent than
non-classic forms. According to El-on et al33, in Israel,
secondary bacterial infections can be effective on both
clinical forms of the disease and size of the cutaneous
lesions.
In the current study, among various occupations, the
highest prevalence of CL was detected in school and uni-
versity students. Considering that Isfahan has a semi-arid
and temperate climate, people spend hot summer nights
outdoors and can thus be bitten by sandflies. On the other
hand, most students aged 7–30 yr old and have not been
infected by the disease; they comprise a high percentage
of patients. However, Doroodgar et al34 reported that
CL had the highest prevalence among housewives in
Kashan.
Intralesional glucantime, intramuscular glucantime,
and simultaneous use of intramuscular and intralesional
glucantime were the most common treatment modalities
in all the age groups. However, since most patients had
more than one lesion or had lesions on a sensitive part of
their body (e.g. eyes, inside ears, nose, lips, and genitals)
intramuscular glucantime was the most widely used treat-
ment. A 20-day period of intramuscular glucantime
(Specia, France) injections (20 mg/kg/day) seems to be
the best method to treat CL in Iran and especially in
Isfahan. The reasons include expansion of CL35, identi-
fying different species of Leishmania due to the exclu-
sive effect of fluconazole, itraconazole, and ketoconazole
on L. major22, lack of knowledge on the therapeutic ef-
fect of pentamidine36, 37, and the recurrence of disease
after treating with allopurinol38, 39. Nevertheless, patients
are recommended to be examined for the presence of car-
diac, renal, hepatic and blood diseases before treating with
glucantime.
CONCLUSION
According to our findings, the City of Isfahan is an
important area with high CL infection rate in Isfahan Prov-
ince and even in Iran. Although the number of recorded
cases of CL was 1315 in one year, the actual number can
be much higher. This issue undoubtedly requires more
accurate and comprehensive research. We also found gen-
der, age, nationality, place of residence, and occupation
to play major roles in the occurrence of the disease. More-
over, the disease was found to possess a seasonal pattern
of incidence. More time and efforts have thus to be paid
for increasing public awareness about transmission ways,
prevention, and complications of infectious diseases, es-
pecially CL. Such efforts should be performed with more
interaction between university hospitals and health cen-
ters in endemic and hyperendemic provinces. The impor-
tance of mass media and mass communication at the right
time cannot be neglected in this regard.
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